What's new?

Sofinnova Partners Raises €472 ($548) Million to Form Largest Early-Stage Healthcare VC Fund in Europe

European venture capital firm has raised €1 billion in the last 12 months across its expanding life science investment platform PARIS, France – October 19,¬ 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the close of its latest earl...

Henrijette Richter appointed Managing Partner of Sofinnova Partners

BioAmber Signs Its First Succinic Acid Take-­‐or-­‐Pay Contract Contract with PTT-­‐MCC Biochem, a joint venture between Mitsubishi Chemical and PTT PCL

• Contract guarantees sales volume for Sarnia plant during its first three years ofoperation • Agreement ensures BioAmberis the principal supplier to a key emerging buyer of succinic acid • PTTMCC selection of BioAmber as supplier validates bio-­‐succinic cost competitiveness and quality

Plus de 1 00 00 patients ont bénéficié de la technologie auto¬apposante de STENTYS

Paris, le 15 septembre 2011 : STENTYS (FR0010949404 – STNT), société de technologie médicale qui commercialise le premier et le seul stent auto¬apposant pour le traitement de l’infarctus du myocarde, annonce aujourd’hui que son stent autoapposant a été implanté dans plus de 1 000 patients dans le monde.

Inside's ICAO-Lite platform open doors for TIL Technologies

First Commercial ICAO-Lite Deployment Provides Secure, Intelligent Credentials for both Access Control and Identity

1